when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Wegovy · news · pharmadog

← back to Wegovy

News mentioning Wegovy

133 stories

19dNovo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechfiercebiotech

21dNovo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendisfiercebiotech

21dNovo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandbiospace

21dCorbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofifiercebiotech

21dNo more Nordisk as Novo goes it alone amid rebranding pushfiercebiotech

26dWebinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Marketsbiospace

26dTelemedicine company offers GLP-1s for addictionstat

27dKrazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12endpoints

27dStructure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropbiospace

Sep 4, 26Menarini signs $771M deal to take Gan & Lee GLP-1 to European marketfiercebiotech

Aug 28, 26Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace

Aug 28, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and morestat

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 26, 26Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealedbiospace

Aug 25, 26Lilly takes oral obesity race abroad with UK launch of Foundayobiospace

Aug 24, 26Roche commits to lean-mass preservation with Hanmi obesity dealbiopharma dive

Aug 21, 26Novo Nordisk starts trialing lower maintenance doses of oral Wegovybiospace

Aug 21, 26How cost and perception could reshape the GLP-1 marketbiopharma dive

Aug 19, 26STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and morestat

Aug 19, 26Enveda’s exercise-simulating obesity tablet clears early clinical testbiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 18, 26Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

Aug 17, 26Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winfiercebiotech

Aug 14, 26Skye and Redx form new entity with $125M to advance fibrosis assetsfiercebiotech

Aug 13, 26STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and morestat

Aug 12, 26Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightbiospace

Aug 11, 26Scholar Rock rejigs approval filing after FDA flags violations at Novo plantbiospace

Aug 11, 26After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’fiercebiotech

Aug 11, 26Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsstat

Aug 7, 26Novo Nordisk’s CFO on the oral Wegovy rollout and beyondfiercebiotech

← prevpage 2 of 5next →